Grazyna Teresa Kochan-rekin lankidetzan egindako argitalpenak (22)

2024

  1. Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies

    British Journal of Cancer, Vol. 130, Núm. 5, pp. 869-879

  2. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

  2. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. CAR-T Cells for the Treatment of Lung Cancer

    Life, Vol. 12, Núm. 4

  2. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  3. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  4. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  5. Cutting-Edge CAR Engineering: Beyond T Cells

    Biomedicines, Vol. 10, Núm. 12

  6. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

    Cells, Vol. 11, Núm. 15

  7. How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 17

  8. How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 17

  9. Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination

    Cancers, Vol. 14, Núm. 18

  10. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  3. Hyperprogressive disease: Main features and key controversies

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  4. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

2019

  1. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses

    Molecular Therapy, Vol. 27, Núm. 11, pp. 1892-1905

2017

  1. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

    Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829